Auxo Firm Directory · Independent Research Profile

Geneva Glen Capital

Geneva Glen Capital states that it invests in proven private companies with leading market positions, significant growth potential, and stable cash flows. Its published criteria include U.S. and Canadian headquarters, platform EBITDA of $2 million to $20 million, and $10 million to $50 million of capital invested per deal.

Key takeaway

What stands out about Geneva Glen Capital

Geneva Glen Capital focuses on control investments, change-of-control transactions, industry consolidations, corporate divestitures, and strategic add-ons for platform companies. It publicly lists a $2 million to $20 million platform EBITDA range and industry focuses spanning services, healthcare, manufacturing, packaging, specialty chemicals, and other areas.[1][2][3][4][5][6][7]

What does Geneva Glen Capital invest in?

Geneva Glen Capital is a Chicago-based private equity firm founded in 2010. The firm states that it invests in proven private companies with leading market positions, significant growth potential, and stable cash flows, while working with management teams to establish and execute value-creation and growth plans.

Official materials describe a family-office-oriented private equity structure backed by family offices and other institutional investors.[1][2][8]

Geneva Glen states that it seeks returns by investing in growing companies rather than using financial-engineering tactics. Its published approach includes conservative leverage and a focus on building long-term value.

The firm states that its patient capital and flexible investment mandate can support both short- and long-term portfolio-company needs. It primarily focuses on equity but can invest throughout the balance sheet.[1]

Owners evaluating a financial buyer can compare the offer with independent valuation analysis, understand how acquirers approach transactions through Auxo’s buy-side M&A process guide, and consider whether a full or partial sale best fits their objectives.

Published criteria: The firm's investment-parameters page states a platform-company EBITDA focus of $2 million to $20 million and $10 million to $50 million of capital invested per deal. It also states that additional equity may be invested through partnerships with like-minded co-investors.[3]

What should a business owner evaluate before considering a transaction with Geneva Glen Capital?

Owners evaluating Geneva Glen can compare their company’s characteristics with the firm’s stated criteria: a proven private business, a leading market position, significant growth potential, stable cash flows, U.S. or Canadian headquarters, and $2 million to $20 million of platform EBITDA.

The firm’s published control orientation, management-team partnership model, meaningful equity participation, flexible capital approach, and stated interest in strategic add-ons are factors to clarify in discussions. Owners should also confirm current capital availability, valuation methodology, rollover-equity expectations, leverage, governance rights, and the intended ownership horizon for the proposed investment.[1][2][3]

01

What current capital is available for new platform investments and add-ons

Geneva Glen states that it invests $10 million to $50 million of capital per deal, can partner with like-minded co-investors for additional equity, and pursues strategic add-ons for platform companies. Current availability is not established by those published criteria and should be confirmed directly.[3]
02

Does the firm require control, or will it consider a minority investment for the specific opportunity

Current investment-parameters materials emphasize change-of-control transactions, while the firm’s approach states that it primarily backs incumbent management teams and can support mutually desired management transitions. The specific control requirement for an opportunity should be clarified.[1][3]
03

How are valuation, leverage, rollover equity, earn-outs, and management incentive pools determined

The materials describing Geneva Glen’s conservative leverage and meaningful equity participation do not establish how valuation, rollover equity, earn-outs, or management incentive pools would be determined for a particular transaction.[1]

What companies does Geneva Glen Capital target?

The firm’s stated criteria center on proven private companies with leading market positions, significant growth potential, and stable cash flows. Its platform-company EBITDA focus is $2 million to $20 million, and its stated capital investment per deal is $10 million to $50 million.

Geneva Glen states that it primarily backs incumbent management teams, is open to mutually desired management transitions, and seeks to align incentives through meaningful equity participation. Additional equity capital may be available through partnerships with like-minded co-investors.[1][2][3]

Geneva Glen publicly lists business and consumer services, consumer products, environmental services, education and training, healthcare, niche industrial manufacturing, packaging, publishing/media/information services, specialty chemicals, and value-added distribution as industry-focus areas.

The firm’s investment-parameters page states that it is not interested in high-technology, retail, restaurants, real estate, defense, or early-stage companies.[3]

Geneva Glen’s published geography focus is companies headquartered in the United States or Canada.[3]

Geneva Glen states that its transaction focus includes change-of-control transactions, industry consolidations, and corporate divestitures. It also pursues strategic add-ons for platform companies.

The firm reports that portfolio company Salon Freedom acquired nine Sola Salon locations in Houston on August 10, 2023, expanding to 60 locations across Pennsylvania, New Jersey, Tennessee, and Texas.[3][5]

Publicly identified examples include Salon Freedom, Envision Home Health & Hospice, Dianne’s Fine Desserts, Southeastern Health Care at Home, and EZ Shipper Racks. Geneva Glen reported the completed March 2022 recapitalization of Salon Freedom and the April 2021 acquisition of Envision Home Health & Hospice.

Its executive operating partner model can involve operating executives serving as part-time advisors, co-investors, board members, active chairmen, CEOs, or other ongoing senior executives. The firm states that these executives may contribute industry expertise to investment theses and value-creation plans.[2][4][6][7][8]

  • On August 10, 2023, Geneva Glen reported that portfolio company Salon Freedom acquired nine Sola Salon locations in Houston.
  • On April 12, 2022, Geneva Glen reported the completed March 2022 recapitalization of Salon Freedom and the April 2021 acquisition of Envision Home Health & Hospice.
  • On November 1, 2022, Geneva Glen announced the sale of Dianne’s Fine Desserts to Dessert Holdings.
  • On August 10, 2021, Geneva Glen announced the sale of Southeastern Health Care at Home to AccentCare.
  • On September 13, 2018, Geneva Glen announced the acquisition of EZ Shipper Racks in partnership with CEO Ned Tomasevic and operating partner Jerry Halamuda.
[2][5][6][7][8]

What is not clear from Geneva Glen Capital's public investment criteria?

The Geneva Glen release for the Dianne’s Fine Desserts sale states that the transaction terms were not disclosed. The release for the Southeastern Health Care at Home sale likewise states that the terms were not disclosed.

The Salon Freedom Houston acquisition release identifies the nine-location acquisition and operating expansion but does not disclose transaction consideration or valuation. The release describing the Envision Home Health & Hospice acquisition identifies the acquisition and operating geography but does not disclose transaction consideration or valuation.[2][5][6][7]

Questions to ask when evaluating Geneva Glen Capital as a buyer or investment partner

What current capital is available for new platform investments and add-ons?
Geneva Glen states that it invests $10 million to $50 million of capital per deal, can partner with like-minded co-investors for additional equity, and pursues strategic add-ons for platform companies. Current availability is not established by those published criteria and should be confirmed directly.[3]
Does the firm require control, or will it consider a minority investment for the specific opportunity?
Current investment-parameters materials emphasize change-of-control transactions, while the firm’s approach states that it primarily backs incumbent management teams and can support mutually desired management transitions. The specific control requirement for an opportunity should be clarified.[1][3]
How are valuation, leverage, rollover equity, earn-outs, and management incentive pools determined?
The materials describing Geneva Glen’s conservative leverage and meaningful equity participation do not establish how valuation, rollover equity, earn-outs, or management incentive pools would be determined for a particular transaction.[1]
What governance rights and operating involvement would Geneva Glen seek?
The firm states that it works with management teams and may partner with operating executives serving in roles including board members, active chairmen, CEOs, and other senior executives. The governance and operating arrangements for a specific investment should be confirmed.[2][4]
What is the expected ownership horizon for the proposed investment?
The materials describing Geneva Glen’s patient capital and focus on building long-term value do not specify an expected ownership horizon for a specific investment.[1]
Which current portfolio companies remain active, and what add-on acquisition capacity is available?
Geneva Glen publicly describes strategic add-ons for platform companies and reports add-on activity by Salon Freedom. The current active portfolio and available add-on capacity should be confirmed directly.[3][5]

Sources & research notes

Public-source research
  1. Official website / firm overview
  2. Services / capabilities
  3. Industry / market focus
  4. Investment approach
  5. Transaction / portfolio evidence
  6. Transaction / portfolio evidence
  7. Transaction / portfolio evidence
  8. Transaction / portfolio evidence
Prepared and reviewed by: Auxo Capital AdvisorsEvidence standard: Public-source verification

How this profile was researched

Auxo profiles are prepared from publicly available primary and authoritative sources and reviewed for entity identity, factual support and disclosure consistency. When a fact cannot be supported by the reviewed public record, the profile identifies it as something to confirm directly rather than inferring it.

Independent profile & regulatory context

Independent research profile

This profile was prepared by Auxo Capital Advisors from publicly available information believed to be reliable and is provided solely for informational and educational purposes. It is not an endorsement, recommendation, ranking, solicitation, or representation regarding the profiled firm, its services, qualifications, transaction experience, regulatory status, financial condition, or suitability for any particular person, company, transaction, or investment.

Information obtained from third-party and public sources may be incomplete, inaccurate, outdated, or subject to change, and Auxo Capital Advisors makes no representation or warranty, express or implied, as to its accuracy, completeness, or timeliness. Readers should conduct their own independent diligence and consult appropriate professional advisers before engaging any advisor, intermediary, investor, lender, acquirer, or other transaction counterparty.

Broker-dealer and securities disclosure

Auxo Capital Advisors is an affiliate of Weild & Co., Member FINRA | SIPC. Securities-related activities and securities transactions are conducted through Weild & Co.

Nothing contained on this page constitutes an offer to sell, an offer to purchase, or a solicitation of an offer to buy or sell any security, investment product, or financial instrument. Nothing on this page constitutes investment advice, a recommendation regarding any security, or a recommendation to enter into any transaction with the profiled firm or any other party.

Any securities transaction, capital-raising engagement, investment-banking engagement, or other securities-related activity involving Auxo Capital Advisors or Weild & Co. is subject to applicable regulatory requirements, internal review and approval, suitability and other applicable diligence requirements, and the terms of a separate written engagement or transaction agreement, as applicable.

Inclusion of a third-party firm in this directory does not imply affiliation with, sponsorship by, endorsement by, or any other relationship with Auxo Capital Advisors or Weild & Co. unless expressly stated otherwise.